Pursuant to the agreement, the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) will focus on identifying drug candidates from a program already receiving support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Bristol-Myers has rights to develop and commercialize the products resulting from the collaborative research program.
VCNDD medicinal chemistry director Craig Lindsley said, "We all look forward to a productive collaboration with Bristol-Myers Squibb, which brings tremendous expertise and a strong commitment to advancing the program."
Under the agreement, Vanderbilt University will earn upfront payment and multi-year research funding to continue to discover additional compounds and is entitled to receive milestones and royalties based on developmental success and worldwide sales of the drugs resulting from the collaboration.
Bristol-Myers research senior vice president Francis Cuss said, "We are thrilled to have the opportunity to work with the Vanderbilt Center for Neuroscience Drug Discovery’s highly regarded scientists and laboratories to potentially find a way to help patients with Parkinson’s disease."